FDA QMSR is Now Mandatory: Post-Deadline Compliance Verification

As of February 2, 2026, the FDA's Quality Management System Regulation (QMSR) is mandatory for all medical device manufacturers in the US. No grace period. No extensions.

If you completed your QMSR transition before the deadline, this is your verification checklist — the items FDA inspectors are prioritizing first. If you're still working on it, here's what to address immediately.

Here's what you need to know about the regulation and how to verify your QMS is compliant now that QMSR is in effect.

What Is QMSR and What Changed on February 2?

The QMSR is the FDA's modernized replacement for the Quality System Regulation (21 CFR Part 820) that governed medical device manufacturing since 1996. The final rule was published on February 2, 2024, with a two-year transition period.^[1]

That transition period ended February 2, 2026 — QMSR is now the law.

The biggest change? The QMSR incorporates ISO 13485:2016 by reference, harmonizing FDA requirements with international standards used by regulatory authorities worldwide. This means your quality management system now needs to align with both FDA expectations and global best practices.^[2]

Translation: If you sell medical devices in the US, your QMS must comply with QMSR. The regulation is now in effect and FDA inspections are proceeding under the new framework.

The 5 Most Significant Changes from QSR to QMSR

Let's cut through the regulatory speak. Here's what actually changed:

1. ISO 13485:2016 Is Now the Foundation

The QMSR incorporates ISO 13485:2016 and ISO 9000:2015 Clause 3 by reference. You can access these standards in read-only format through the ANSI Incorporated by Reference Portal (no subscription required).^[1]

What this means for you: Your QMS documentation needs to demonstrate compliance with ISO 13485:2016 requirements, not just legacy QSR language.

2. Previously Exempt Documents Are Now Fair Game

Under the old QSR, certain documents were exempt from FDA inspection:

• Internal audit reports
• Management review minutes
• Supplier audit reports

Under QMSR, those exemptions are gone. FDA inspectors can now request and review all of these documents.^[1]

What this means for you: If your internal audits or management reviews have been... let's say "informal," that needs to change. Now.

3. Design Traceability Is Mandatory

ISO 13485:2016 requires explicit traceability from design inputs to design outputs. Previously, this was considered a best practice. Now it's a requirement.^[3]

What this means for you: You need documented evidence linking every design requirement to its verification and validation.

4. New FDA Inspection Process

The Quality System Inspection Technique (QSIT) was retired on February 2, 2026. The FDA has implemented a new inspection process aligned with QMSR requirements.^[1]

What this means for you: Expect inspections to focus more heavily on ISO 13485:2016 compliance and the documents that were previously exempt.

5. Risk Management Integration

ISO 13485:2016 has tighter integration with ISO 14971 (risk management). Risk analysis must now be woven throughout your design and development process, not tacked on at the end.^[3]

QMSR Compliance Verification Checklist

Now that QMSR is in effect, these are the items FDA inspectors are prioritizing in their first inspections under the new regulation.

Phase 1: Assess and Document

Day 1-2: Run a rapid gap assessment

• Compare your current QMS procedures against ISO 13485:2016 requirements
• Identify missing or outdated documentation
• Flag any previously-exempt documents that aren't inspection-ready

Day 3-4: Prioritize gaps by risk

• What would cause an FDA inspector to issue a 483 observation?
• What gaps affect multiple system requirements?
• What can be fixed quickly vs. what needs ongoing improvement?

Day 5-7: Document your QMSR compliance approach

• Create a QMSR Transition Summary documenting how your QMS meets the new requirements
• Update your Quality Manual to reference ISO 13485:2016
• Prepare a cross-reference matrix (QSR → QMSR → ISO 13485:2016)

Phase 2: Close Critical Gaps

Priority 1: Previously exempt documents

• Review internal audit reports for the past year. Are they detailed enough for FDA review?
• Check management review minutes. Do they document required elements (objectives, process performance, improvement actions)?
• Audit your supplier audit reports. Are findings, corrective actions, and follow-up documented?

Priority 2: Design controls

• Verify traceability from design inputs to outputs for recent product developments
• Document any missing trace links
• Update your design control procedure to explicitly require traceability matrices

Priority 3: Training records

• Document personnel training on QMSR changes
• Update training materials to reflect ISO 13485:2016 requirements
• Brief key staff on what to expect during inspections

Phase 3: Inspection Readiness

Conduct a mock inspection

• Simulate an FDA inspection with focus on QMSR-specific changes
• Practice explaining your QMSR compliance approach to inspectors
• Identify and close any remaining documentation gaps

Prepare your inspection response team

• Designate who will interact with FDA inspectors
• Brief them on QMSR changes and where to find supporting documentation
• Practice responding to questions about ISO 13485:2016 compliance

Final review

• Ensure all critical procedures are revision-controlled and current
• Verify electronic and paper records are accessible
• Confirm backup documentation exists for key quality systems

Common QMSR Myths (Debunked)

Myth #1: "If I have ISO 13485 certification, I'm automatically compliant with QMSR."

Reality: No. ISO 13485 certification does not exempt you from FDA inspections or guarantee QMSR compliance. The FDA explicitly states that holding an ISO certificate is neither required nor accepted as proof of compliance.^[1]

Why? Because Notified Body audits and FDA inspections have different scopes and different levels of scrutiny.

Myth #2: "MDSAP audits cover FDA requirements, so I'm good."

Reality: MDSAP and FDA inspections are separate processes. While MDSAP incorporates FDA requirements, the FDA retains independent inspection authority and follows different procedures than MDSAP auditors.^[1]

Myth #3: "There's a transition period after February 2."

Reality: There is no transition period. QMSR compliance is mandatory on February 2, 2026. The FDA may review records created before the effective date to assess compliance.^[1]

Myth #4: "Only new products need to comply with QMSR."

Reality: All medical devices manufactured after February 2, 2026 must be produced under a QMSR-compliant quality system, regardless of when the device was originally approved.

What FDA Inspectors Will Look For First

Based on the regulatory changes and industry guidance, expect FDA inspectors to focus on:^[3]

1. Previously exempt documentation - Internal audits, management reviews, and supplier audits will be heavily scrutinized since they're now accessible for the first time.
2. ISO 13485:2016 alignment - Inspectors will verify your procedures actually reflect ISO requirements, not just QSR language with "QMSR" slapped on top.
3. Design control traceability - Expect detailed questions about how you link design inputs to outputs, especially for recent product developments.
4. Risk management integration - How is ISO 14971 implemented throughout your design and development process?
5. Process validation - Particularly for sterile devices and those with complex manufacturing processes.

The FDA has indicated that the new inspection process will be more stringent than typical Notified Body audits. Be ready for deeper questioning and more thorough document review.^[3]

Need to Verify Your QMSR Compliance?

Whether you transitioned early or are still working through gaps, knowing exactly where you stand is critical. FDA inspections under QMSR are already happening, and inspectors are trained specifically on the new requirements.

Aligntra's platform can run a comprehensive gap assessment against ISO 13485:2016 and QMSR requirements in hours, not weeks. Our AI-powered analysis identifies exactly which procedures need updates, which documents need creation, and which gaps pose the highest regulatory risk.

Then our consulting team can help you close those gaps. Fast.

Traditional gap assessments take 3-4 weeks just for the discovery phase. We deliver a detailed gap report with prioritized recommendations in 3-4 hours. That gives you more time to actually fix issues instead of just documenting them.

Learn more about Aligntra's rapid gap assessment service

Frequently Asked Questions

The Bottom Line

QMSR is now mandatory. February 2, 2026 was not a suggestion — it was the effective date, and it has passed.

Every medical device manufacturer in the US must demonstrate QMSR compliance. The FDA is conducting inspections under the new regulation. If you haven't completed your transition, your next inspection is the deadline.

Focus on high-impact gaps: the ones that pose the most regulatory risk and would be most obvious to an inspector. Use Aligntra to identify exactly where your QMS stands.

And if you need help closing those gaps quickly, that's exactly what we built Aligntra to do.

References

1. FDA. "Quality Management System Regulation: Final Rule Amending the Quality System Regulation – Frequently Asked Questions." https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked (Accessed: January 14, 2026)
2. Federal Register. "Medical Devices; Quality System Regulation Amendments." Vol. 89, No. 23 (February 2, 2024). https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments
3. Morgan Lewis. "February 2, 2026 Is Quickly Approaching—Are You QMSR Ready?" October 2024. https://www.morganlewis.com/pubs/2024/10/february-2-2026-is-quickly-approaching-are-you-qmsr-ready (Accessed: January 14, 2026)